AR118131A1 - Composición farmacéutica que comprende compuesto derivado de benzoimidazol - Google Patents
Composición farmacéutica que comprende compuesto derivado de benzoimidazolInfo
- Publication number
- AR118131A1 AR118131A1 ARP200100446A ARP200100446A AR118131A1 AR 118131 A1 AR118131 A1 AR 118131A1 AR P200100446 A ARP200100446 A AR P200100446A AR P200100446 A ARP200100446 A AR P200100446A AR 118131 A1 AR118131 A1 AR 118131A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- composition including
- derivative compound
- recurrence
- benzoimidazole derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se refiere a una composición farmacéutica para prevenir la recurrencia de la enfermedad por reflujo gastroesofágico, que comprende un derivado de benzoimidazol. La composición farmacéutica de la presente puede prevenir de manera eficaz la recurrencia de la enfermedad por reflujo gastroesofágico sin ningún efecto secundario durante un largo período de tiempo. Reivindicación 1: La composición farmacéutica para prevenir la recurrencia de la enfermedad por reflujo gastroesofágico, que comprende tegoprazán que es un compuesto representado por la fórmula química (1) o una sal farmacéuticamente aceptable del mismo en una cantidad de 25 mg en forma de tegoprazán.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20190018801 | 2019-02-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR118131A1 true AR118131A1 (es) | 2021-09-22 |
Family
ID=72143624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200100446A AR118131A1 (es) | 2019-02-18 | 2020-02-18 | Composición farmacéutica que comprende compuesto derivado de benzoimidazol |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20220125764A1 (es) |
| EP (1) | EP3927340B1 (es) |
| JP (3) | JP2022520276A (es) |
| KR (2) | KR20200100552A (es) |
| CN (1) | CN113473984A (es) |
| AR (1) | AR118131A1 (es) |
| AU (1) | AU2020225520B2 (es) |
| BR (1) | BR112021016212A2 (es) |
| CA (1) | CA3130562A1 (es) |
| DK (1) | DK3927340T3 (es) |
| EA (1) | EA202192286A1 (es) |
| ES (1) | ES3053893T3 (es) |
| FI (1) | FI3927340T3 (es) |
| JO (1) | JOP20210226A1 (es) |
| LT (1) | LT3927340T (es) |
| MX (1) | MX2021009893A (es) |
| MY (1) | MY207182A (es) |
| PH (1) | PH12021551989A1 (es) |
| PT (1) | PT3927340T (es) |
| RS (1) | RS67488B1 (es) |
| SG (1) | SG11202108949PA (es) |
| SM (1) | SMT202500424T1 (es) |
| UA (1) | UA129026C2 (es) |
| UY (1) | UY38588A (es) |
| WO (1) | WO2020170106A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230127317A (ko) * | 2020-12-30 | 2023-08-31 | 에이치케이이노엔 주식회사 | 테고프라잔과 비스테로이드성 항염증 약물을 포함하는약학적 조성물 |
| KR20250118583A (ko) | 2024-01-30 | 2025-08-06 | 진양제약주식회사 | 테고프라잔을 포함하는 제약 조성물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007072146A1 (en) * | 2005-12-19 | 2007-06-28 | Pfizer Japan Inc. | Chromane substituted benzimidazoles and their use as acid pump inhibitors |
| SG11201710006PA (en) * | 2015-06-08 | 2018-01-30 | Cj Healthcare Corp | Use of benzimidazole derivatives for nocturnal acid breakthrough |
| KR101829685B1 (ko) * | 2016-07-28 | 2018-02-19 | 씨제이헬스케어 주식회사 | 안정성 및 용해도가 개선된 주사용 조성물 |
| KR101829706B1 (ko) * | 2016-09-21 | 2018-02-19 | 씨제이헬스케어 주식회사 | 벤즈이미다졸 유도체의 산부가염 |
| KR101829705B1 (ko) * | 2016-09-21 | 2018-02-19 | 씨제이헬스케어 주식회사 | 안정성이 향상된 주사용 조성물 |
| KR101960357B1 (ko) * | 2016-12-26 | 2019-03-20 | 씨제이헬스케어 주식회사 | 벤즈이미다졸 유도체를 포함하는 신규한 제제 |
-
2020
- 2020-02-17 KR KR1020200018849A patent/KR20200100552A/ko not_active Ceased
- 2020-02-17 SM SM20250424T patent/SMT202500424T1/it unknown
- 2020-02-17 MX MX2021009893A patent/MX2021009893A/es unknown
- 2020-02-17 JP JP2021547865A patent/JP2022520276A/ja active Pending
- 2020-02-17 LT LTEPPCT/IB2020/051296T patent/LT3927340T/lt unknown
- 2020-02-17 ES ES20759153T patent/ES3053893T3/es active Active
- 2020-02-17 CA CA3130562A patent/CA3130562A1/en active Pending
- 2020-02-17 CN CN202080015631.4A patent/CN113473984A/zh active Pending
- 2020-02-17 PH PH1/2021/551989A patent/PH12021551989A1/en unknown
- 2020-02-17 BR BR112021016212-7A patent/BR112021016212A2/pt unknown
- 2020-02-17 MY MYPI2021004705A patent/MY207182A/en unknown
- 2020-02-17 FI FIEP20759153.8T patent/FI3927340T3/fi active
- 2020-02-17 AU AU2020225520A patent/AU2020225520B2/en active Active
- 2020-02-17 WO PCT/IB2020/051296 patent/WO2020170106A1/en not_active Ceased
- 2020-02-17 DK DK20759153.8T patent/DK3927340T3/da active
- 2020-02-17 EP EP20759153.8A patent/EP3927340B1/en active Active
- 2020-02-17 UA UAA202105244A patent/UA129026C2/uk unknown
- 2020-02-17 PT PT207591538T patent/PT3927340T/pt unknown
- 2020-02-17 RS RS20251162A patent/RS67488B1/sr unknown
- 2020-02-17 EA EA202192286A patent/EA202192286A1/ru unknown
- 2020-02-17 US US17/429,732 patent/US20220125764A1/en active Pending
- 2020-02-17 SG SG11202108949PA patent/SG11202108949PA/en unknown
- 2020-02-17 JO JOP/2021/0226A patent/JOP20210226A1/ar unknown
- 2020-02-18 AR ARP200100446A patent/AR118131A1/es unknown
- 2020-02-18 UY UY0001038588A patent/UY38588A/es unknown
-
2023
- 2023-07-07 JP JP2023111840A patent/JP2023126955A/ja active Pending
-
2025
- 2025-05-21 JP JP2025084528A patent/JP2025122089A/ja active Pending
- 2025-06-12 KR KR1020250077086A patent/KR20250090275A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3927340A4 (en) | 2022-11-02 |
| CN113473984A (zh) | 2021-10-01 |
| KR20200100552A (ko) | 2020-08-26 |
| PH12021551989A1 (en) | 2022-08-15 |
| UY38588A (es) | 2020-09-30 |
| JP2025122089A (ja) | 2025-08-20 |
| MY207182A (en) | 2025-02-04 |
| RS67488B1 (sr) | 2025-12-31 |
| SMT202500424T1 (it) | 2026-01-12 |
| AU2020225520A1 (en) | 2021-10-14 |
| SG11202108949PA (en) | 2021-09-29 |
| FI3927340T3 (fi) | 2025-11-26 |
| LT3927340T (lt) | 2025-12-29 |
| WO2020170106A1 (en) | 2020-08-27 |
| UA129026C2 (uk) | 2024-12-25 |
| PT3927340T (pt) | 2025-11-18 |
| JP2023126955A (ja) | 2023-09-12 |
| DK3927340T3 (da) | 2025-11-03 |
| MX2021009893A (es) | 2021-09-14 |
| JOP20210226A1 (ar) | 2023-01-30 |
| EA202192286A1 (ru) | 2021-11-18 |
| EP3927340B1 (en) | 2025-09-03 |
| CA3130562A1 (en) | 2020-08-27 |
| ES3053893T3 (en) | 2026-01-27 |
| JP2022520276A (ja) | 2022-03-29 |
| EP3927340A1 (en) | 2021-12-29 |
| AU2020225520B2 (en) | 2025-08-14 |
| KR20250090275A (ko) | 2025-06-19 |
| US20220125764A1 (en) | 2022-04-28 |
| BR112021016212A2 (pt) | 2021-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2634490T3 (es) | Derivados de ácido napht-2-ylacetico para tratar el sida | |
| CL2023000196A1 (es) | Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos | |
| CO2023008018A2 (es) | Nuevos agentes antivirales derivados de la espiropirrolidina | |
| CO2022001862A2 (es) | Regímenes de dosificación para inhibidores orales del factor d del complemento | |
| MX2015006039A (es) | Derivados de pirimidin-2, 4-diamina para el tratamiento de cancer. | |
| AR117814A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
| AR106237A2 (es) | Inhibidores heterocíclicos de la aspartil proteasa, sus sales farmacéuticamente aceptables | |
| MX2024006689A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| MX2016001400A (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| AR099134A1 (es) | Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina | |
| CR9721A (es) | Compuestos de carbamato para utilizar en el tratamiento de desordenes neurodegenerativos | |
| CR11510A (es) | Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer | |
| AR087107A1 (es) | Compuesto inhibidor de la señalizacion de la trayectoria notch | |
| CO6480931A2 (es) | Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas. | |
| AR106141A1 (es) | Métodos e intermediarios para la preparación de derivados de ácidos biliares | |
| AR124688A2 (es) | Una pirimidina sulfonamida o un tautómero del mismo, o una sal farmacéuticamente aceptable del mismo | |
| AR117920A1 (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| AR105319A1 (es) | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| MX2017003780A (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| MX2020004930A (es) | Compuestos de biarilo sustituido novedosos como inhibidores de indolamina 2,3-dioxigenasa (ido). | |
| AR105821A1 (es) | COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T | |
| AR062390A1 (es) | Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas | |
| CL2022002817A1 (es) | Inhibidores de replicación del virus de inmunodeficiencia humana | |
| AR118131A1 (es) | Composición farmacéutica que comprende compuesto derivado de benzoimidazol |